{"meta":{"id":"https:\/\/api.iclient.ifeng.com\/ipadtestdoc?aid=ucms_7wd955WYSNd","type":"doc","o":"1","documentId":"ucms_7wd955WYSNd"},"body":{"newStatus":"1","documentId":"ucms_7wd955WYSNd","staticId":"ucms_7wd955WYSNd","title":"恩华药业:加巴喷丁胶囊通过仿制药一致性评价","shareTitle":"恩华药业:加巴喷丁胶囊通过仿制药一致性评价","thumbnail_doc":"","thumbnail":"","source":"证券时报","author":"","editorcode":"weMedia","editTime":"2020-05-20 17:02:26","updateTime":"2020\/05\/20 17:02:26","wapurl":"http:\/\/\/\/finance.ifeng.com\/c\/7wd955WYSNd","introduction":"","wwwurl":"http:\/\/\/\/finance.ifeng.com\/c\/7wd955WYSNd","commentsUrl":"ucms_7wd955WYSNd","commentCount":0,"text":"
证券时报e公司讯,恩华药业(002262)5月20日晚公告,公司于近日收到国家药监局核准签发的关于“加巴喷丁胶囊”的《药品补充申请批件》,公司加巴喷丁胶囊通过仿制药质量和疗效一致性评价。加巴喷丁胶囊适应症:1、疱疹感染后神经痛:用于成人疱疹后神经痛的治疗。2、癫痫:用于成人和12岁以上儿童伴或不伴继发性全身发作的部分性发作的辅助治疗。也可用于3~12岁儿童的部分性发作的辅助治疗。<\/p>","img":[],"summary":"证券时报e公司讯,恩华药业(002262)5月20日晚公告,公司于近日收到国家药监局核准签发的关于“加巴喷丁胶囊”的《药品补充申请批件》,公司加巴喷丁胶囊通过仿","sharesummary":"证券时报e公司讯,恩华药业(002262)5月20日晚公告,公司于近日收到国家药监局核准签发的关于“加巴喷丁胶囊”的《药品补充申请批件》,公司加巴喷丁胶囊通过仿","commentType":"0","wemediaEAccountId":"706","showclient":"0","shareurl":"https:\/\/ishare.ifeng.com\/c\/s\/v002WMvc2GoI6ESOMZrPm--gCK76OcCbRTJYsv4ILWNffV--0__","praise":"0","like_num":"0"}}